Citations

Clear

499 citation(s) found for "Tracy, PB".

Myc super-enhancer dynamics in T-ALL
Tousinas, Georgios , Toliopoulos, Vasili , Tracy, Melissa, Emmanuel, Akinola Olumide , Khazaie, Khashayarsha , Papamarcaki, Thomais, Bergsagel, P. Leif , Gounari, Fotini

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5030-5030

10.1182/blood-2025-5030 Get It

Abstract Mutations in non-coding regulatory elements are increasingly recognized as critical drivers of cancer development and progression. Among these, structural alterations such as duplications of super-enhancers (SEs), large clusters of enhancers that regulate key oncogenes, have emerged as significant contributors to oncogenesis. In T-cell acute lymphoblastic leukemia (T-ALL), a particularly aggressive hematologic malignancy, SE duplications have been identified in approximately 5% of human cases. These duplications frequently involve a non-coding region located approximately 1.3 megabases downstream of the Myc oncogene, a region known as N-Me. Despite the growing recognition of the role of SE duplications in T-ALL, functional studies to determine their molecular origins and contributions to leukemogenesis have been limited, largely due to the absence of suitable and genetically tractable preclinical models. This gap in knowledge hinders both our understanding of disease pathogenesis and our ability to design targeted therapeutic interventions. Here, we report the generation and characterization of a novel genetically engineered mouse model of T-ALL that spontaneously develops oncogenic SE duplications at the Myc locus. This model offers the first spontaneous in vivo system to investigate the origin, regulation, and oncogenic function of SE duplications. This model was created by conditionally stabilizing β-catenin in CD4⁺CD8⁺ double-positive (DP) thymocytes in combination with targeted deletion of the transcription factor HEB. This combination is sufficient to drive the development of aggressive T-cell leukemias that consistently harbor duplications of the N-Me super-enhancer. This finding recapitulates the genomic alteration observed in a subset of human T-ALL and provides a unique platform for mechanistic studies. We further demonstrate that the molecular events leading to SE duplication and oncogenic Myc activation unfold in a stepwise manner. At the preleukemic stage, stabilization of β-catenin alone is sufficient to enhance recruitment of HEB to the N-Me region. The simultaneous loss of HEB greatly increased chromatin accessibility at the N-Me enhancer. This altered chromatin landscape permits aberrant binding of transcription factors including TCF-1, which plays a critical role in T-cell development and leads to N-Me SE activation associated with significant three-dimensional chromatin reorganization. Chromosome conformation analyses in the leukemic cells reveal the formation of a novel chromatin loop that brings the activated N-Me SE into close spatial proximity with the Myc promoter, enabling oncogenic Myc transcription. These findings uncover a novel mechanistic pathway by which β-catenin and HEB interact to reshape the enhancer landscape and three-dimensional chromatin architecture, ultimately promoting SE duplication and aberrant Myc expression in T-ALL. β-catenin appears to play a dual role, first facilitating HEB recruitment under physiological conditions and then, upon HEB loss, permitting the reprogramming of enhancer activity through chromatin opening and ectopic transcription factor binding. Our data suggest that the cooperative interplay between signaling pathways and transcriptional regulators at enhancer elements can initiate structural genomic changes that drive malignancy. This work provides a long-sought preclinical model that faithfully mirrors key features of human T-ALL. Our findings open new avenues for understanding how non-coding regulatory mutations arise and exert oncogenic effects and have the potential to provide insights that may extend beyond T-ALL to other cancers driven by enhancer dysregulation. Moreover, by revealing molecular intermediates such as β-catenin, HEB, and TCF-1 in the regulation of enhancer activity, our findings identify potential therapeutic targets to disrupt the oncogenic enhancer-promoter interactions that underlie Myc-driven leukemogenesis.
CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel
McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory, Muffly, Lori, Muffly, Lori , Muffly, Lori , McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2396-2396

10.1182/blood-2025-2396 Get It

Abstract Introduction: CD19-directed CAR T-cell (CAR-T) therapy has substantially improved clinical outcomes for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, notable toxicities are associated with CAR-T, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Variable practice patterns have emerged regarding the use of CRS/ICANS prophylaxis (ppx) via corticosteroids and/or other pharmacologic agents, but the utility of these approaches on reducing CRS or ICANS following CAR-T in B-ALL remains unknown. Thus, we utilized the Real-World Outcomes Collaborative for CAR T in ALL (ROCCA) database to evaluate associations between ppx and the development and severity of CRS or ICANS following brexucabtagene autoleucel (brexu-cel) for B-ALL. Methods: Adult patients (pts) who received standard-of-care brexu-cel for relapsed/refractory B-ALL across 40+ US centers were included. Primary endpoints were the incidence of CRS and ICANS within 28 days of CAR-T infusion. Secondary endpoints included timing of CRS and ICANS onset, progression-free survival (PFS) and overall survival (OS). Univariable and multivariable logistic regression evaluated associations between ppx and incidence of CRS/ICANS; KM and log-rank methods were used for survival analyses. Results: A total of 378 pts were included: 53 pts (14.0%) received CRS/ICANS ppx and 325 (86.0%) received no ppx. Ppx agents included steroids only (26.4%), steroid and anakinra (52.8%), anakinra only (15.1%), and steroid and tocilizumab (5.7%). Pts in the ppx group had a higher proportion of Hispanic pts (64% vs 34%), Ph-like (36% vs 19%) and a lower proportion had 0-5% bone marrow blasts at apheresis (38% vs 53%). The ppx and no ppx groups were similar in age, prior therapies, CAR-T indication, and marrow blasts >50%. Cumulative incidence of any grade (gr) CRS was 94% with ppx and 86% with no ppx (p=0.025), of any gr ICANS was 53% with ppx and 51% with no ppx (0= 0.85). Cumulative incidence of gr 3-4 CRS was 9% in the ppx group and 10% in the no ppx group (p=1.00), of gr 3-4 ICANS was 26% in the ppx group and 29% in the no ppx group (p=0.71). Median time to onset for any gr CRS or any gr ICANS was identical in the ppx and no ppx cohorts (CRS: 5 days, range ppx 1-9 days, no ppx 0-14 days; ICANS: 7 days, ppx 1-20 days, no ppx 0-16 days). Univariate logistic regression analyses showed no significant association between ppx and the incidence of gr 2-4 CRS (OR 1.34, 95% CI: 0.75-2.40, p=0.326) or gr 3-4 ICANS (OR 0.88, 95% CI: 0.46-1.70, p=0.708). Multivariate analysis adjusting for ethnicity, leukemia genetic sub-type, and pre-apheresis disease burden similarly found no significant associations between ppx and gr 2-4 CRS (adjusted OR 1.06, 95% CI: 0.55-2.01, p=0.870) or gr 3-4 ICANS (OR 1.23, 95% CI: 0.59-2.55, p=0.584). When comparing steroid-only ppx (N=14) to steroid combinations or other drug ppx (N=39), there was no significant differences in gr 2-4 CRS (57% vs 44%, p=0.345) or gr 3-4 ICANS (43% vs 21%, p=0.115). Comparing cumulative incidence of dexamethasone (dex) exposure, pts in the ppx group had numerically greater dex exposure than pts in the no ppx group, with median (range) dosing of 182 mg (10-1386mg) and 100mg (1-4000mg), respectively. Finally, we found no significant differences in PFS or OS based on ppx. Median PFS was 9.6 months in the ppx group vs 13.3 months in the no ppx group (p=0.646) and median OS was 17.2 months in the ppx group vs 34.4 months in the no ppx group (p=0.170). Conclusions: In this large cohort of adult patients with R/R ALL receiving brexu-cel CAR-T therapy, prophylaxis intended to prevent CRS/ICANS was ineffective at reducing CRS/ICANS incidence, time to onset, or overall steroid exposure. Furthermore, PFS and OS were comparable between patients who received prophylaxis and those who did not. In the absence of prospective trials in B-ALL, these data suggest that current strategies of CRS/ICANS prophylaxis has limited benefit.
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Rein, Lindsay , Boggs, Nathan A. , Yi, Cecilia Y. Arana , Elberink, Hanneke Oude , Radia, Deepti , Reiter, Andreas , Piris‐Villaespesa, Miguel , Dybedal, Ingunn , Panse, Jens , Vachhani, Pankit , Kirshenbaum, Arnold S. , Vaughn, Jennifer E. , Cerquozzi, Sonia , Fahrenholz, John M., Pomares, Helena , Üstün, Celalettin , Herrscher, Richard, Barète, Stéphane , Rivera, Candido E., Vadas, Peter , McCulloch, Derek, Keohane, Clodagh, Schafhausen, Philippe, Pilla, Amanda, Zhang, Jenna, Sun, Lei , Shah, Nisha , Jolin, Hina, Easton, Rachael, Sachs, Jessica, Bose, Prithviraj , Modena, Brian D. , Sabato, Vito , Hartmann, Karin , Akin, Cem , George, Tracy I. , Yi, Cecilia Arana , Oh, Stephen T. , Hunter, Anthony M. , Castells, Mariana , Livideanu, Cristina Bulai , Daele, Paul Van , Álvarez‐Twöse, Iván , Taparia, Minakshi , Mital, Andrzej , Hus, Marek , Romano, Alessandra , Lansigan, Frederick , Papayannidis, Cristina , Rondoni, Michela , Manning, Michael, Guilarte, Mar , Bernstein, Jonathan A. , Elena, Chiara , Orfali, Nina M. , Mannelli, Francesco , Shah, Nisha, Siebenhaar, Frank , DeAngelo, Daniel J.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 80-80

10.1182/blood-2025-80 Get It

Abstract Background: Systemic mastocytosis (SM) comprises a spectrum of subtypes characterized by neoplastic mast cell (MC) infiltration of tissues and release of MC mediators. Non-advanced SM (NonAdvSM), including indolent SM (ISM), smoldering SM (SSM), and bone marrow mastocytosis (BMM) subtypes, is the most prevalent form of SM. NonAdvSM can be associated with debilitating symptomology which can significantly impair quality of life. The gain-of-function somatic KIT c.2447 C>T (p.D816V) mutation is found in up to 95% of patients with SM. Bezuclastinib (CGT9486) is an oral, potent, and selective type 1 tyrosine kinase inhibitor with activity against KIT D816V. Results from Summit (NCT05186753) Part 1 informed the recommended phase 2 dose (100 mg QD bezuclastinib) for Part 2. We report topline results from the 24-week assessment of Summit Part 2. Methods: Summit is a multi-center, randomized, double-blind, placebo (PBO)-controlled Phase 2 trial of bezuclastinib in patients with NonAdvSM who had inadequate symptom control despite best supportive care (BSC) medications. The primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range 0–110), which is a fit-for-purpose patient-reported outcome measure of NonAdvSM symptom severity. Key secondary endpoints included the proportion of patients with ≥50% reduction in serum tryptase, KIT p.D816V variant allele frequency (VAF), bone marrow (BM) MC burden, and MS2D2 TSS, ≥30% TSS reduction. Patients were randomized 2:1 to receive 100mg QD bezuclastinib + BSC or PBO + BSC. Results: As of May 22, 2025, 179 patients were enrolled in Part 2: 119 were randomized to receive bezuclastinib and 60 to placebo. Patients enrolled were representative of the NonAdvSM population with moderate to severe symptoms. Median age (range) was 51 (23-78) years; 65.9% female; mean (SD) baseline MS2D2 TSS 55.6 (19.8); 82% of patients had ISM, 11% had BMM, and 7% had smoldering SSM. At baseline, median (range) KIT p.D816V VAF in whole blood, BM MC burden, and serum tryptase was 0.25% (0-34%), 10% (1-75%), and 40 (6-692) ng/mL, respectively. Bezuclastinib demonstrated statistically significant superiority to placebo on all primary and key secondary endpoints. At Week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean [95% CI] MS2D2 TSS change: –24.3 [–27.6 to –21.1] vs –15.4 [–19.6 to –11.2]; placebo-adjusted difference: –8.9 points; P=0.0002). A ≥50% reduction in serum tryptase was achieved in 87.4% of bezuclastinib-treated patients vs 0% on placebo (P<0.0001). Significantly more patients receiving bezuclastinib achieved ≥50% reductions in KIT D816V VAF, serum tryptase, BM MCs (P<0.0001), MS2D2 TSS (P=0.01), and ≥30% reduction in MS2D2 TSS (P=0.0004). Most treatment-emergent adverse events (TEAEs) were low grade (gr; 70% Gr 1) and reversible. The most common TEAEs (≥10%) in any treatment group and occurring in greater frequency in the bezuclastinib arm were hair color changes (69.5% vs 5.0%), altered taste (23.7% vs 0%), nausea (22.0% vs 13.3%), increased ALT/AST (22.0% vs 6.6%), headache (17.8% vs 11.7%), alopecia (11.9% vs 3.3%), and increased ALP (10.2% vs 3.3%). TEAEs (≥10%) that occurred more often in the placebo group were diarrhea (13% vs 18%), dizziness (10% vs 12%), fatigue (7% vs 12%), and arthralgia (6% vs 15%). ALT/AST elevations ≥Gr 3 were experienced by 5.9% of patients. The only hepatic adverse events (AEs) reported were transient lab abnormalities; none required hospitalization. Treatment-related AEs requiring dose reductions occurred in 11% of patients receiving bezuclastinib. All discontinuations (5.9%) due to treatment-related AEs were due to transaminase elevations; all fully resolved. Conclusions: At 24-weeks, bezuclastinib 100 mg QD demonstrated statistically and clinically significant improvements in symptom burden and biomarkers of disease vs placebo in patients with NonAdvSM. The treatment was generally well-tolerated and effective across a population that is representative of the real-world NonAdvSM population, including SSM. These results support the use of bezuclastinib to reduce SM burden and symptoms in pts with NonAdvSM, and a potentially disease-modifying impact.
KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)
Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Muffly, Lori, Shah, Bijal, Aldoss, Ibrahim, Muffly, Lori , Muffly, Lori , Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Shah, Bijal, Aldoss, Ibrahim

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3365-3365

10.1182/blood-2025-3365 Get It

Abstract Introduction: Brexu-cel is a highly effective treatment for R/R B-ALL, with complete responses achieved in 71% of patients (pts) treated in the pivotal ZUMA-3 trial. Patients with B-ALL with high-risk (HR) genetics are known to have inferior outcomes with chemotherapy, but little is known about the influence of HR ALL genetics on responses to chimeric antigen receptor (CAR)-T in adults. In this study, we assessed the impact of HR ALL genetics on outcomes in a large cohort of adult patients treated with brexu-cel for R/R Philadelphia chromosome (Ph)-negative B-ALL. Methods: Patient characteristics and outcomes were obtained from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) database which includes data from 40 U.S. centers. NCCN guidelines (NCCN Guidelines in Oncology, ALL v2.2025) were used to define HR B-ALL genetics; lack of HR genetics was defined as standard-risk (SR). The primary outcome was event-free survival (EFS), defined as lack of response, disease progression, or death from any cause. Secondary outcomes were overall survival (OS), relapse free survival (RFS) and response rates including complete response (CR), CR incomplete count recovery (CRi), measurable residual disease negative CR (MRD-) by flow or NGS and progressive disease (PD). Multivariable models were adjusted for age, pre-infusion blast percentage, prior allo-HCT, and post CAR-T allo-HCT (modeled as a time-varying covariate). Results: The cohort included 286 pts: 169 with HR and 117 with SR B-ALL. The HR cohort included TP53m (n=24, 14%), KMT2Ar (n=16, 9%), CRLF2r (n=65, 39%) and other HR genetics such as JAK2 and other Ph-like, IKZF1, complex cytogenetics (n=64, 38%). Relative to SR pts, HR pts were more commonly Hispanic (50% vs 28%). HR and SR pts had similar disease burden pre-apheresis (>5% blasts: 58% vs 53%), prior blinatumomab (60% vs 58%), prior inotuzumab (42% vs 46%), and prior allo HCT (27% vs 37%). The presence of CNS disease (11% HR vs 12% SR) and extramedullary disease (EMD, 22% HR vs 29% SR) at apheresis was also similar. CR/CRi was achieved in 90.5% of evaluable HR pts (n=147) and 90.2% of evaluable SR pts (n=102); MRD- rates were also similar between HR and SR pts at 78.9% and 78.2% respectively. In unadjusted analyses, EFS did not significantly differ between HR pts (median 9.6 mos; 1-yr: 46%, 95% CI 38%-54%) and SR pts (median 11.6 mos; 1-yr: 48%, 95% CI 38%- 58%). Median RFS (HR: 12.2 mos, SR: 13.3 mos) and median OS (HR: 22.4 mos, SR: 21.0 mos) were also similar. Multivariable models demonstrated no significant associations between HR B-ALL and EFS (HR 1.09, 95% CI 0.73-1.63), RFS (HR 1.13, 95% CI 0.71-1.80), or OS (HR 0.96, 95% CI 0.62- 1.48) relative to SR ALL. 28% of HR patients and 21% of SR patients underwent consolidative allo-HCT. Among the HR subgroup, CR/CRi rate was lowest in KMT2Ar (71%) relative to TP53m (95%), CRLF2r (95%), and other HR genetics (89%). The median EFS was lowest in KMT2Ar (4.1 mos), followed by TP53m (6.9 mos), CRLF2r (11.6 mos), and other HR (11.1 mos). Median OS was also lowest in KMT2Ar (6.8 mos) vs 22.4 mos in TP53m and not reached in CRLF2r or other HR. PD was highest in KMT2Ar pts (29%), as compared to 11% HR other, 10% SR, and 5% TP53 and CRLF2r. The rate of relapse among those that achieved CR across the groups was similar and ranged between 28% -40%. Rates of CD19 negative relapse were similar between all subgroups (13%-15%), however 21% of KMT2A pts underwent myeloid transformation as compared 0% for TP53 and CRLF2 pts, and 2% among other HR and SR pts. 25% of KMT2Ar patients underwent consolidative allo-HCT as compared to 32% CRLF2 pts, 29% TP53 pts, 25% other HR pts and 21% SR pts. Multivariable models evaluating the different genomic subgroups demonstrated that relative to SR B-ALL, only KMT2Ar was associated with inferior OS (HR 3.17, 95% CI 1.53-6.58, p=0020). No associations were seen between HR subgroups and EFS. Conclusion: To our knowledge, this analysis represents the largest examination of adult B-ALL recipients of CAR-T assessed by genomic risk group. We found that response rates and survival outcomes following brexu-cel were similar among HR and SR B-ALL pts, including pts with TP53m and CRLF2r. However, pts with KMT2Ar had lower response rates and dismal EFS and OS, with higher rates of PD and myeloid transformation at relapse, suggesting that alternative strategies are necessary to improve outcomes for patients with R/R KMT2Ar B-ALL.
Lessons Learned in Clinical Trial Recruitment: A Partnership Between a Genomic Research Study and the Discover Together Biobank
Childers-Buschle, Kristin , Tracy, Morgan E, Myers, Melanie F. , McGowan, Michelle L. , Prows, Cynthia A. , Pauciulo, M., Myers, Melanie F

Mayo Clinic

Biopreservation and Biobanking | November 22, 2025 | Volume: 24 | Issue: 4 | Pages: 291-300

10.1177/19475535251391616 | PMID 41271210 Get It

Collaboration between biobanks and research teams is essential for advancing scientific research, particularly in studies involving human subjects; however, various challenges can hinder success. We shed light on key obstacles and challenges encountered during a partnership between a clinical trial and an institutional biobank at a pediatric hospital. In aiming to recruit pediatric biobank participants for a genomic clinical research study, key challenges included low-yield recruitment tactics, independent operations and structures of the biobank and research teams, and transition to a new biobank model resulting in struggles with participant reengagement. This article explores some of the obstacles experienced by the research and biobanks teams, while providing key lessons aimed at guiding others in planning future collaborations for trial recruitment, enrollment, and implementation. We also highlight the significant benefits that can arise when biobanks and research teams work together strategically.
The not-so-shortcomings of seated saline suppression testing in primary aldosteronism
Stowasser, Michael , Eisenhofer, Graeme , Schlaich, Markus P. , Bell, Damon A. , Yang, Jun , Mulatero, Paolo , Young, William F., Williams, Tracy Ann , Reincke, Martín , Yang, Jun , Mulatero, Paolo , Williams, Tracy Ann , Reincke, Martin , Stowasser, Michael , Horvath, Andrea R.

Mayo Clinic

European Journal of Endocrinology | November 14, 2025 | Volume: 193 | Issue: 6 | Pages: L36-L37

10.1093/ejendo/lvaf232 | PMID 41251236 Get It

SUN-409 Postoperative adrenal insufficiency in patients with mild autonomous cortisol secretion
Salama, Bahaa, Hamidi, Oksana, Wang, Tracy S, Sada, Alaa, Habra, Mouhammed Amir, Dogra, Prerna, Dackiw, Alan P B, Oltmann, Sarah Catherine, Mirfakhraee, Sasan, Lingvay, Ildiko, Mckenzie, Travis, Foster, Trenton, Lyden, Melanie, Dy, Benzon, Brondani, Vânia Balderrama, Bancos, Irina, Salama, Bahaa, Hamidi, Oksana, Wang, Tracy S, Sada, Alaa, Habra, Mouhammed Amir, Dogra, Prerna, Dackiw, Alan P B, Oltmann, Sarah Catherine, Mirfakhraee, Sasan, Lingvay, Ildiko, Mckenzie, Travis, Foster, Trenton, Lyden, Melanie, Dy, Benzon, Brondani, Vânia Balderrama, Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.379 Get It

Abstract Disclosure: B. Salama: None. O. Hamidi: None. T.S. Wang: None. A. Sada: None. M.A. Habra: None. P. Dogra: None. A.P. Dackiw: None. S.C. Oltmann: None. S. Mirfakhraee: None. I. Lingvay: None. T. Mckenzie: None. T. Foster: None. M. Lyden: None. B. Dy: None. V. Balderrama Brondani: None. I. Bancos: None. Background: Patients with mild autonomous cortisol secretion (MACS) are at risk for adrenal insufficiency (AI) after unilateral adrenalectomy. Guidelines recommend initiating glucocorticoid replacement post-adrenalectomy. However, identifying patients at risk and accurately diagnosing AI can enable individualized management. Objectives: Determine the prevalence, duration and predictors of postoperative AI after unilateral adrenalectomy for MACS and compare baseline and peak cortisol post cosyntropin stimulation test (CST) In diagnosing AI. Methods: We conducted a multicenter retrospective cohort study of patients with MACS who underwent unilateral adrenalectomy and post-operative CST evaluation between January 1, 2013, and August 31, 2024. MACS was defined as cortisol >1.8 mcg/dL following overnight administration of 1 mg dexamethasone (DST-cortisol). AI was diagnosed when post-operative day 1 early morning baseline cortisol was <10 μg/dL and/or CST peak cortisol was <18 μg/dL. Baseline and peak cortisol levels were considered concordant when both met cut-offs. Biochemical (BSS) and clinical (CSS) severity scores were calculated. Results: Among 281 adults with MACS (80% women, median age 57 years, interquartile range [IQR] (47-64), the median adenoma size was 3.0 cm (IQR, 2.3-3.9), and 62 (22%) had bilateral disease. The median BSS was 4 (IQR, 3-5), and the median CSS was 6 (IQR, 2-11). Postoperative AI was diagnosed in 153 (54.5%) patients. A multivariable analysis showed that a higher BSS (OR = 1.17, 95% CI 1.01-1.36) and younger age at diagnosis (OR = 0.64, 95% CI 0.50-0.81), but not sex, BMI, or laterality, were associated with AI. Diagnosis of AI was concordant based on the baseline and peak CST cortisol cutoffs in 78% of patients. Diagnosis of AI was discordant in 22%: in 35 patients (12%), baseline cortisol was <10 μg/dL, but CST peak cortisol was ≥18 μg/dL, and in 28 cases (10%), baseline cortisol was ≥10 μg/dL, but CST peak cortisol was <18 μg/dL. Patients with bilateral MACS were more likely to have discordant results (32% vs. 19%, P < 0.001). During a median postoperative follow-up period of 15.4 months, 108 patients (70.6%) recovered from AI. The median time to recovery was 3.9 months (IQR, 3-5.9), with 41% recovering by 3 months, 60% by 6 months, and 73% by 12 months. The median time to recovery was associated with baseline BSS: mild: 3 months, moderate: 4.7 months, and severe: 14.5 months. Conclusion: We found that more than half of patients with MACS develop postoperative AI, with 50% recovering by 4 months post-surgery. BSS was associated with both the development and duration of AI. Baseline and CST peak cortisol results were concordant only in 78% of patients, thus performing both should be considered for an accurate diagnosis of AI. Presentation: Sunday, July 13, 2025
Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Ma
Kirtek, Timothy , Chen, Weina , Harris, Jaryse , Bagg, Adam , Foucar, Kathryn , Tam, Wayne , Orazi, Attilio , Hasserjian, Robert P. , Wang, Sa A. , Ng, David P. , Reichard, Kaaren K. , Symes, Emily , Zhang, Xinmin , Weinberg, Olga K. , Kirtek, Timothy J , Wang, Sa A , Ng, David P , Shi, Min , Zhang, Xinmin , Arber, Daniel A , Orazi, Attilio , Hsi, Eric D. , George, Tracy I. , Arber, Daniel A.

Mayo Clinic

American Journal of Hematology | October 18, 2025 | Volume: 101 | Issue: 1 | Pages: 70-78

10.1002/ajh.70116 | PMID 41108621 Get It

ABSTRACT The World Health Organization (WHO) 5th Edition and International Consensus Classification (ICC) have continued to delineate more genetically defined acute leukemias. Both recognize genetic aberrations associated with myelodysplastic syndromes/neoplasms (MDS) as defining MDS‐related AML (AML‐MR). Mutations in RUNX1 are included in this category in the ICC, but not WHO. The current classifications are unclear on how acute leukemias with ambiguous lineage (ALAL), including those of mixed lineage (MPAL) and those without a defined lineage (AUL), should be categorized in the presence of such mutations. Our multi‐institutional study aims to determine the significance of RUNX1 mutation in ALAL compared to de novo AML. Newly diagnosed MPAL, AUL, and AML with RUNX1 mutations were collected. ALAL with MDS‐related cytogenetics, BCR::ABL1 , KMT2A rearrangements, or ZNF384 or BCL11b abnormalities were excluded. We analyzed 17 cases of ALAL and 71 cases of AML that met inclusion criteria. ALAL‐ RUNX1 and AML‐ RUNX1 showed overlapping mutational landscapes with frequent comutations in MDS‐associated genes. No ALAL‐ RUNX1 or AML‐ RUNX1 cases showed concomitant TP53 mutation. ALAL‐ RUNX1 had more bone marrow blasts and more karyotypic abnormalities; however, neither impacted survival, nor did RUNX1 variant allele frequency (VAF). Survival analysis revealed similarly poor outcomes between them. AML‐directed therapies and allogeneic hematopoietic stem cell transplant trended toward improved survival in ALAL‐ RUNX1; however, it did not reach significance. Our results suggest ALAL‐ RUNX1 is associated with younger age, higher blasts, and more karyotypic abnormalities, but has similar clinical and genetic features and outcomes to AML‐ RUNX1 . Our findings suggest, like other MR mutations, RUNX1 ‐mutated ALALs should be included within AML‐MR.
Accelerating eSource scale-up in oncology clinical trials: The i~HD Task Force initiative
Kalra, Dipak, Acito, Tracy, Ammour, Nadir, Basset, Paul, Castleyn, Peter, Caldow, Ross, Couvert, Camille, Cramer, Amy, Harrison, Chris, Holtzem, Joeri, Mariappan, P., Jacobs, Paul, Fransson, Lars, Berthou, Véronique, Jackson, Laurice, Wetzel, Nancy, Thompson, C. C. , Klein, Sharon , Kaoukdji, Fakhry, Ward, Michael, Lengfellner, Joe, Patruno, Anna, Snow, Dawn, Virchow, Isabel , Fritsche, Angela, Coorevits, Pascal , Sundgren, Mats , Sundgren, Mats , Maes, Christophe, Kalra, Dipak, Ammour, Nadir, Burge, Sarah , Caldow, Ross, Couvert, Camille, Cramer, Amy, Mariappan, Pavitra, Jacobs, Paul, Wetzel, Nancy, Thompson, Christopher, Klein, Sharon, Green, Robert, Kaoukdji, Fakhry, Ward, Michael, Nensa, Felix , Lengfellner, Joe, Patruno, Anna, Snow, Dawn, Fritsche, Angela

Mayo Clinic

Cambridge Prisms: Precision Medicine | October 14, 2025 | Volume: 3 | Issue: No issue available | Pages: No page available

10.1017/pcm.2025.10004 | PMID 41306345 Get It

Abstract eSource – particularly EHR-to-EDC – is an emerging paradigm in clinical research that enables automated transfer of electronic health record (EHR) data into electronic data capture (EDC) systems, with the potential to reduce site burden, improve data quality and accelerate oncology clinical trial workflows. However, widespread implementation remains limited due to technical, regulatory and operational barriers. To address these challenges, the European Institute for Innovation through Health Data (i~HD) launched the eSource Scale-Up Task Force in 2024. This multi-stakeholder initiative brings together leading oncology centres and pharmaceutical sponsors to establish a consensus-driven roadmap for eSource adoption. Central to this effort are three foundational resources: readiness criteria for early adopters, a performance indicator framework for monitoring success and an operational playbook to guide implementation. This article provides a structured overview of the Task Force’s objectives, collaborative model and outputs, with specific attention to its focus on interoperability, regulatory alignment and real-world validation. While initially developed for oncology, the Task Force’s framework is applicable across therapeutic areas characterized by data-intensive workflows.
Digital Planning-Based Technologies to Support Memory-Related Functioning in Older Adults with Mild Cognitive Impairment: A Systematic Scoping Study
Sriranganathan, Aswen , Kathiravelu, Shaylene, Sikora, Lindsey , McClymont, Shekinah, Locke, Dona E.C. , Chandler, Melanie , Shandera‐Ochsner, Anne L., Chan, Adrian D. C. , Rajabiyazdi, Fateme , Santos, Octavio A. , Trudel, Chantal , Jaiswal, Atul , Thomas, Neil , Locke, Dona E C , Li, Tracy

Mayo Clinic

Journal of Ageing and Longevity | October 8, 2025 | Volume: 5 | Issue: 4 | Pages: 42

10.3390/jal5040042 Get It

Background: Mild cognitive impairment (MCI) is a precursor to dementia, with a prevalence of over 15% among community dwellers, with significant economic and social implications. Despite preserved autonomy in daily living, individuals with MCI face challenges in handling everyday technology and memory-related tasks, necessitating digital interventions, such as digital planning-based technologies to support cognitive functioning. Objective: The aim of this study is to identify and summarize available research literature on available digital planning-based technologies to support memory-related functioning in older adults with MCI. Specifically, this study seeks to (1) document the types and functions of these technologies, (2) report their effectiveness, and (3) identify gaps in the current evidence. Methods: A comprehensive literature search of four databases (Medline, Embase, APA PsycINFO, and CINAHL) was conducted in accordance with Arksey and O’Malley’s scoping review methodological framework from inception to February 6, 2024, without restrictions. Inclusion criteria focused on peer-reviewed studies involving adults aged 50 or older with diagnosed cognitive impairment, specifically using digital planning-based technologies for memory support. Results: From 1854 sources, 8 studies were included. Five categories of digital planning-based technologies were identified: (1) reminders and alarms, (2) electronic calendars, (3) digital memory notebooks, (4) digital visual mapping, and (5) smart-home integration. Several studies reported improved task performance, memory recall, and executive function, with digital memory notebooks and visual mapping software showing greatest impact on functional independence. While interventions were generally well-received, usability challenges and low adherence were common, often linked to technological familiarity and motivation. Conclusions: Digital planning-based technologies show promise in supporting memory-related functioning in older adults with MCI. While studies report positive outcomes, more research is needed to refine these tools, evaluate long-term effects, and ensure integration into daily life. Expanding the evidence base will be key to improving accessibility and effectiveness for this population.